Fortifeye Super Omega 3 Max

This new glaucoma device is the smallest implantable medical device in the world and is the latest advancement in glaucoma care

The Optejet® ophthalmic drug device is designed to precisely administer medication to the eye, potentially treating patients' conditions through gentler, more efficient dosing.

Entrepreneur-eye surgeon continues his family's legacy in the field of ophthalmology, as Eyenovia's new Chairman

While traditional eye drop bottles require hand-eye coordination and deliver four to five times more medication than the human eye can hold, the Optejet® dispenser's human-centric design administers an easier, more accurate and appropriate dose directly where it is needed in the eye.

Time To Be Bold is a national public service awareness campaign helping the three million Americans 55 or older who are struggling with low vision regain their independence.

3D Human Tissue Retina Vasculature model provides a new and novel approach to rapidly and efficiently screening numerous therapies for diabetic retinopathy and diabetic macular edema.

Appointment reflects Glauconix Biosciences' expansion of their 3D Human Tissue model platform within the Ophthalmology space and brings their second commercial model closer to market

Board-Certified Ophthalmologist Dr. Savak Teymoorian of Harvard Eye Associates assisted in the research and development of new glaucoma drug.

Diaton Tonometer is a unique and innovative tonometry instrument, unlike all others; allows to accurately measure Intraocular Pressure (IOP) through the eyelid and sclera without touching the eyeball. With Diaton use, there is no risk of infection or need for sterilization, as there is no contact with the mucous membrane. Zero-contact with the cornea or influence of corneal biomechanics on Diaton IOP results provides more accurate glaucoma diagnosis.

Appointment reflects Glauconix Biosciences' readiness to expand their commercial footprint and business verticals in the field of ophthalmology and beyond

The ComfortPack™ is a dependable solution for anesthetizing the eye prior to intravitreal injections.

New Wearable Technology Helps People With Low Vision Regain Visual Independence

Funding by Early Stage Venture Capital Firm, Arab Angel and Strategic Partners

Dr Somdutt Prasad, one of the best retinal specialists, spoke on Diabetic Retinopathy at the event.

The global Ophthalmology devices market is expected to reach $42.0 billion by 2021. This report analyzes the ophthalmology devices market in terms of market revenue ($ million) for all segments.

Besides short sightedness and dry eyes, the most common eye diseases are macular degeneration, cataract and glaucoma. Do you know the difference between these 3 eye diseases?

Did you know that you could have glaucoma and not know it? January is Glaucoma Awareness Month, so take the time to learn more about glaucoma. Early detection and treatment can save your sight.

Key-Whitman Eye Center is keeping up with the latest technology in the diagnosis and treatment of dry eyes and was recently certified by TearLab as an "Accredited Dry Eye Center".

Michigan Optometric Association emphasizes importance of comprehensive eye exams during National Glaucoma Awareness Month

Sonoma County's award-winning Petaluma acupuncturist, David Russell, L.Ac, announces new specialized acupuncture treatments for degenerative vision loss

Barbara Wirostko, Senior Medical Director, Team Lead Ophthalmology, Pfizer will give a presentation at GTCbio's 2nd Annual Ocular Disease Drug & Discovery Conference, May 27 - 28, 2010 in Boston, MA.

New England Eye Center
Acquires Framingham Ophthalmology Practice
Pediatric Ophthalmologist Richard J. Blocker, MD Joins Boston-Based Practice

FOR IMMEDIATE RELEASE